A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
Completed
Vertex Pharmaceuticals Incorporated
Phase 1
2012-01-01
The purpose of this study is to evaluate the relative bioavailability, safety, and
tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
Completed
Vertex Pharmaceuticals Incorporated
Phase 2
2006-06-01
Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa
2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV)
ribonucleic acid (RNA) levels
Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
Completed
Vertex Pharmaceuticals Incorporated
Phase 2
2006-08-01
Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon
Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C
virus (HCV) ribonucleic acid (RNA) levels
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
Completed
Vertex Pharmaceuticals Incorporated
Phase 2
2007-02-01
The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an
investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a
(Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV, Copegus®) in people with genotype 1
hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment
of interferon therapy.
Study of Telaprevir in Subjects With Hepatic Impairment
Completed
Vertex Pharmaceuticals Incorporated
Phase 1
2007-09-01
The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir
following administration of multiple oral doses to subjects with moderate and severe hepatic
impairment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
